MeSH D053842 - microsatellite instability
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D042822:Genomic instability
0 Companies
0 Drugs
Success rate
D053842: 
Microsatellite instability
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Merck & CoPembrolizumab Keytruda  2014-09-04 $29,482 M Y2024 
Clinical Trials
Historical Success Rate
Phase 1
86%
6/7
Phase 2
9%
1/11
Phase 3
50%
1/2
Approved: 1Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use